Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
Author:
Publisher
Elsevier BV
Subject
General Biochemistry, Genetics and Molecular Biology,Molecular Biology
Reference179 articles.
1. CAR T cell immunotherapy for human cancer;June;Science (80),2018
2. Cytokines in the treatment of cancer;Conlon;J. Interf. Cytokine Res.,2018
3. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance;Park;Exp. Mol. Med.,2018
4. Next generation of immune checkpoint therapy in cancer: new developments and challenges;Marin-Acevedo;J. Hematol. Oncol.,2018
5. The immune revolution: a case for priming, not checkpoint;Vonderheide;Cancer Cell,2018
Cited by 134 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. New immune cell engagers for cancer immunotherapy;Nature Reviews Immunology;2024-01-25
2. End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations;International Journal of Pharmaceutics: X;2023-12
3. Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma;Scientific Reports;2023-11-27
4. Rapid Access to Potent Bispecific T Cell Engagers Using Biogenic Tyrosine Click Chemistry;Bioconjugate Chemistry;2023-11-14
5. Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8+ T-cell immunity towards cancer cells;Cancer Gene Therapy;2023-11-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3